SCANDION ONCOLOGY A/S obtains “Intention to Grant” notice for SCO-101 from the European Patent Office (EPO)

Booking.com

SCANDION ONCOLOGY A/S is pleased to announce that the company has received an “Intention to Grant” notice from the EPO regarding its European patent application 17726573.3, which includes SCO-101 in combination with specific topoisomerase I inhibitors to treat various cancers. The patent will last until 2037.
CEO Nils Brünner comments: 

It is of significant importance that Scandion Oncology now obtains its first patent on its lead drug SCO-101 in the treatment of drug resistant cancer. We have filed additional patents on SCO-101 and are awaiting feedback on these applications.

For

Booking.com

Source: SCANDION ONCOLOGY A/S obtains “Intention to Grant” notice for SCO-101 from the European Patent Office (EPO)

Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.